Thin Outside. Fat Inside. The body composition problem most people never see.
MRI imaging studies have found that a meaningful proportion of adults who appear lean by every external measure are carrying significant fat around their internal organs. This is the TOFI profile. BNRThin Slim+ was developed around a question most supplements ignore: what if body weight and internal body composition are not the same thing? Powered by Lactobacillus gasseri BNR17, studied in a randomised controlled trial.
For decades, we've relied heavily on measurements that cannot distinguish where fat is stored.
The scale measures weight. It does not measure where fat is stored. It cannot see inside the abdominal cavity. It cannot see around the liver, the intestines, or the pancreas. It cannot see visceral fat.
Which means millions of people have been reassured by a number that never measured the thing they were actually worried about. A person can receive a normal BMI reading, look lean in every mirror, wear the same clothing size for a decade — and still carry significant internal fat their external measurements have no way of detecting.
This is not a fringe hypothesis. It is the finding of MRI-based body composition research, documented repeatedly across different populations. The body has an inside. The scale has never seen it.
The scale can only see half the story.
The Visible Body
- Body weight — the number on the scale
- BMI — weight divided by height squared
- Appearance — what the mirror reports
- Clothing size — how clothes fit externally
The Invisible Body
- Visceral fat — stored around internal organs
- Liver fat — hepatic fat accumulation
- Portal circulation — direct metabolic access
- Inflammatory signalling — from visceral tissue
Understanding the invisible side of body composition requires a different approach than weight measurement alone.
A normal weight. An abnormal interior.
Professor Jimmy Bell and his colleagues at Imperial College London used MRI imaging to study the internal body composition of volunteers across a range of body sizes and appearances. What the scans revealed was consistent and counterintuitive: a proportion of participants who appeared lean by every external standard — normal weight, unremarkable waistlines — were carrying abdominal fat at levels their outward appearance gave no indication of.
Bell's team called this the TOFI profile: Thin Outside, Fat Inside. It was not coined to alarm people. It was coined because the gap between external appearance and internal fat accumulation was large enough, and consistent enough, to need a name.
Not everyone with a normal BMI has elevated visceral fat. Not everyone with elevated visceral fat fits the TOFI profile. TOFI is a useful description, not a diagnosis. The only way to know how much visceral fat you carry is through direct measurement — CT imaging, DEXA scanning, or validated clinical assessment.
- People tell you that you're lucky because you can eat anything and stay slim
- Your weight barely changes year to year — but your waist has slowly increased
- Your annual blood tests keep getting "borderline" or "watch this" comments
- You exercise regularly but still carry abdominal softness that doesn't respond
- You wear the same clothing size you always have, but you feel different around the middle
- One or both parents developed type 2 diabetes despite not being visibly overweight
Understanding why this profile exists requires understanding that not all body fat sits in the same location or behaves the same way biologically.
Under the skin
The fat you can see and measure from the outside. It shapes the body's visible profile and responds to diet and exercise in ways the mirror can track.
Around the organs
Stored deep inside the abdominal cavity, surrounding the liver, intestines, and pancreas. It secretes inflammatory compounds and drains directly into the portal vein — which is why researchers treat it as a separate metabolic concern from overall body weight. It produces no visible external signal.
Probiotic research is strain-specific. This formulation is built around one strain.
Research into the relationship between the gut microbiome and internal body composition has expanded significantly. But the findings do not apply evenly across all probiotic products — outcomes observed in trials using one specific bacterial strain do not transfer automatically to other strains, even within the same genus. A product that contains Lactobacillus bacteria and a product whose exact strain was used in a controlled trial are not the same thing.
BNRThin Slim+ is built around Lactobacillus gasseri BNR17 — a single named strain that occurs naturally in the human gut microbiome, originally isolated from human breast milk, and subsequently studied in two 12-week randomised controlled human trials with internal body composition as the focus.
Each sachet is formulated to provide 10 billion CFU, matching the high-dose arm of the 2018 clinical trial.
What researchers think is happening — and why it matters for the TOFI profile.
The gut microbiota influences metabolism through several distinct pathways: short-chain fatty acid production, bile acid metabolism, intestinal barrier integrity, and the regulation of systemic inflammatory signalling. Research has identified associations between gut microbial composition and abdominal fat accumulation in human observational studies.
What the clinical trial measured — including the outcomes that were not significant.
Two peer-reviewed randomised controlled trials have studied BNR17 in humans. Below is the larger, more recent one. We show the full outcome data — not just the positive findings — because a selective reading of trial results is a form of misdirection, and it tends to be discovered.
A 12-week double-blind, placebo-controlled trial in 90 overweight and obese Korean adults.
90 adults (BMI 25–35) were randomised to placebo, low-dose BNR17 or high-dose BNR17 (10 billion CFU/day, the same dose as each BNRThin Slim+ stick) for 12 weeks, with all groups following the same mild diet and activity plan. The trial measured abdominal fat areas by imaging, body composition, and metabolic markers by blood analysis. It was not designed to determine whether BNR17 reduces disease risk.
| Outcome measured | Direction | Result |
|---|---|---|
| Visceral fat area (high dose, primary) | −21.6 cm² vs placebo | Significant |
| Waist circumference | Decreased from baseline in both BNR17 groups — not in placebo | Significant |
| Body weight & BMI | Not reported as significant vs placebo | Not significant |
| Fasting blood glucose | No meaningful difference | Not significant |
| Total cholesterol | No meaningful difference | Not significant |
| LDL, HDL, triglycerides | No meaningful difference | Not significant |
The headline result: at 10 billion CFU a day — the same dose in every BNRThin Slim+ stick — visceral fat area fell by 21.6 cm² more than placebo over 12 weeks. Effect sizes were modest. The trial does not establish BNR17 as a treatment for metabolic conditions — and the authors do not claim this. Biochemical parameters (glucose, lipids) showed no statistically significant differences between groups.
What BNRThin Slim+ does — and what it cannot do alone.
BNRThin Slim+ is a probiotic supplement formulated to support gut microbiome function as part of an overall lifestyle approach. It is designed for the person already managing their caloric intake and activity — who wants strain-specific, research-grounded gut microbiome support as a complement to that approach.
The trial that produced the results above used overweight adults, not the specific TOFI population this product addresses. The science is directionally relevant, not population-specific to you.
- A named probiotic strain with a published 12-week RCT
- Gut microbiome support, studied in controlled conditions
- It adds a gut microbiome component to a broader lifestyle approach
- Formulated with the TOFI metabolic profile in mind
- Dosed at the CFU level used in clinical research
- A fat burner or appetite suppressant
- A treatment for any medical condition
- Validated specifically in the TOFI population
- A product whose biochemical markers were significant in trial
- A substitute for how you eat and move
Standard weight measures may underestimate metabolic risk in some Asian populations.
Multiple large studies, including the Singapore Chinese Health Study and comparative body composition research conducted across East and Southeast Asian cohorts, have found that people of Asian descent accumulate visceral fat at lower body weights and lower BMI thresholds than Western populations.
The ratio of internal to subcutaneous fat is characteristically higher in Asian bodies at equivalent overall weight. This means the external signal — body size, BMI, clothing size — is an even less reliable indicator of internal fat burden in this region than it would be elsewhere.
The World Health Organisation responded to this evidence by recommending revised BMI thresholds for Asian adults: overweight begins at 23, not 25. That is not an administrative footnote. It reflects a recognition that metabolic risk in Asian bodies emerges earlier in the weight spectrum than conventional scales suggest.
The mismatch between visible body size and internal fat accumulation may be particularly relevant in many Asian populations. A Malaysian or Singaporean adult who falls within the normal range on a standard BMI chart may still carry internal fat their weight category does not capture.
The questions worth asking before you buy.
What did the trial actually find — give me the numbers.+
The Kim et al. (2018) trial found 21.6 cm² less visceral fat than placebo at 12 weeks, and waist measurements fell from baseline. Body weight did not differ significantly from placebo. Effect sizes were modest — this is not a dramatic transformation product. The trial results table on this page shows the full outcome data, including the measures that were not significant.
What was not significant: fasting blood glucose, total cholesterol, LDL, HDL, and triglycerides showed no statistically significant differences between groups. BNR17 did not produce measurable metabolic improvements on these markers in the trial conditions.
The trial was conducted in overweight Korean adults — not in the TOFI population (normal weight with elevated internal fat). The findings are directionally relevant to the TOFI profile but have not been separately validated in that population.
Why 10 billion CFU — is that actually the studied dose?+
Yes. The dose in BNRThin Slim+ matches the dose used in the Kim et al. RCT. We state this explicitly because CFU figures on supplement packaging are frequently not tied to any studied dose. In this case, the 10 billion CFU figure is the clinical research dose, standardised to remain viable through the point of consumption.
Who is this designed for — specifically?+
It is intended for adults interested in body composition and gut microbiome support, particularly those who identify with the TOFI concept — a person at or near normal weight who suspects they may carry internal fat their external measurements do not capture. The self-identification section on this page describes the experiential markers that correlate with this profile in research populations.
BNRThin Slim+ assumes you are already managing your diet and activity. It addresses the gut microbiome layer those efforts cannot directly reach or measure.
Why is BNR17 from a human source?+
Lactobacillus gasseri BNR17 was originally isolated from human breast milk — a source of scientific interest because the strain evolved alongside the human gut environment rather than in animal or industrial fermentation contexts. The strain used in BNRThin Slim+ is cultured under controlled manufacturing conditions. What you receive is the standardised, live BNR17 culture at 10 billion CFU — not the original source material.
Is BNRThin Slim+ Halal certified?+
BNRThin Slim+ does not carry JAKIM Halal certification. The BNR17 strain was originally isolated from a human source, which places it outside standard Halal certification pathways. We state this plainly so you can make an informed decision.
Some Islamic scholars apply the principle of Istihalah — transformation through the culturing and fermentation process — to products in this category. The Organisation of Islamic Cooperation's Fiqh Academy has published relevant guidance. We present this as factual context only; the determination of what is permissible is a personal and scholarly matter.
How do I take it?+
BNRThin Slim+ is a green-apple flavoured powder in single-serve sachets for daily use. Follow the directions on your packaging. It is a nutritional supplement and is not intended to diagnose, treat, or manage any medical condition.
I have a diagnosed health condition. Is this appropriate?+
BNRThin Slim+ is a nutritional supplement, not a medical treatment. If you have a diagnosed condition — metabolic, digestive, autoimmune, or otherwise — consult your doctor before use. The clinical research cited here was conducted in generally healthy overweight adults, not in people with specific medical conditions.
Go deeper on visceral fat, TOFI and BNR17®
- L. gasseri BNR17® and visceral fat: what the trials found →
- Is there a probiotic for visceral fat? Why the strain matters →
- Fat loss probiotic: what the evidence supports →
- How to reduce visceral fat: what works →
- TOFI explained: thin outside, fat inside →
- Belly fat after 40: why the waistband changes first →
- Probiotic for belly fat? The fat you can’t pinch →
- Kurus luar, tapi dalam? Body composition vs weight →
- Best Korean probiotic for belly fat in Malaysia →
- BNR17 Malaysia FAQ: genuine, halal, dosage, delivery →
A probiotic supplement developed around the science of internal body composition.
BNRThin Slim+ is formulated for the TOFI profile — normal weight on the outside, a different story on the inside. Powered by Lactobacillus gasseri BNR17: one named strain, four human clinical trials, dosed at the amount studied in that research.